Employees: 1,097
Size Tatva Chintan Pharma Chem (TATVA.NS) is an India Materials company (Chemicals: Specialty) with a market value of $412M, the 941st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,649 on 18 Nov 2026.
Performance Over six months the shares gained 28.6%, against -18.0% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 49.7% over the last twelve months (peer median +5.8%); the operating margin is 13.3% (peer median 5.3%).
Valuation It trades at 49.8× forward earnings against a peer median of 16.5× (most expensive of 8).
Capital Return on invested capital runs 9.0 points below its cost of capital (15.7% WACC).
Next results Next results expected around 21 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹6.50B | ₹5.03B | ₹3.82B | ₹3.93B | ₹4.23B |
| Revenue growth | — | +32% | -3% | -7% | — |
| Gross profit | ₹2.48B | ₹1.07B | ₹464M | ₹725M | ₹928M |
| EBITDA | ₹1.27B | ₹1.00B | ₹374M | ₹678M | ₹675M |
| Net income | ₹629M | ₹421M | ₹57.1M | ₹304M | ₹455M |
| Free cash flow | n/a | -₹841M | -₹524M | -₹337M | -₹1.78B |
| Capital expenditure | n/a | ₹1.14B | ₹763M | ₹1.29B | ₹2.03B |
| Total debt | ₹1.70B | ₹1.20B | ₹364M | ₹143M | ₹1.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TATVA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.4% | -10.3% | 7th lowest of 21 |
| 6-month return | +28.6% | -18.0% | 3rd highest of 21 |
| Distance from 52-week high | -22.0% | -41.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +49.7% | +5.8% | 4th highest of 21 |
| Operating margin | 13.3% | 5.3% | 3rd highest of 21 |
| Forward P/E | 49.8× | 16.5× | most expensive of 8 |
| ROIC minus cost of capital | -9.0 pp | -2.2 pp | 2nd lowest of 21 |
| EV / EBITDA | 31.7× | 8.7× | most expensive of 7 |
| Net debt / EBITDA | 1.2× | 2.4× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tatva Chintan Pharma Chem TATVA.NS | India | $412M | +29% | +50% | 13% | 49.8× | n/a | n/a |
| Guangdong Delian 002666.SZ | China | $410M | -30% | +3% | 0% | n/a | n/a | n/a |
| Oriental Union Chemical 1710.TW | Taiwan | $409M | +41% | +1% | 0% | 16.1× | n/a | n/a |
| Baotou Dongbao Bio-Tech 300239.SZ | China | $408M | -14% | +7% | 7% | n/a | n/a | n/a |
| KPIC 006650.KS | South Korea | $405M | -40% | +11% | 4% | 8.9× | n/a | n/a |
| Ellenbarrie Industrial Gases ELLEN.NS | India | $420M | 0% | +289% | 28% | 24.6× | 42.8% | +14.3% |
| Gevo GEVO | United States | $421M | +4% | +80% | -11% | 24.8× | n/a | n/a |
| Zhejiang Haisen Pharmaceutical 001367.SZ | China | $404M | -24% | +9% | 29% | n/a | -3.9% | +13.4% |
| Braskem S.A. Sponsored ADR Pfd BAK | United States | $421M | -82% | -1% | 1% | 1.6× | n/a | n/a |
| FuJian Nox Bellcow 300132.SZ | China | $422M | -32% | +18% | 7% | 16.5× | -4.3% | -10.5% |
| Koatsu Gas Kogyo 4097.T | Japan | $423M | +10% | +4% | 7% | n/a | -9.6% | +5.1% |
| Qingdao Copton Technology 603798.SS | China | $401M | -43% | -7% | 5% | n/a | 19.9% | +0.9% |
| Nantong Jiangtian Chemical 300927.SZ | China | $425M | -32% | +51% | 5% | n/a | 16.3% | +29.0% |
| Guangdong Tianan New Material 603725.SS | China | $425M | -10% | -12% | 2% | n/a | 19.4% | +29.0% |
| Shanghai Huide Science & Technology 603192.SS | China | $426M | -22% | +10% | 3% | n/a | 9.0% | +10.5% |
| Hubei Shuanghuan Science and Technology 000707.SZ | China | $399M | -11% | -10% | -10% | n/a | 56.5% | +3.1% |
| Vishnu Chemicals VISHNU.NS | India | $398M | -8% | +14% | 13% | 20.1× | n/a | n/a |
| UPC Technology 1313.TW | Taiwan | $435M | +9% | -1% | 0% | n/a | 38.2% | +2.5% |
| Zhejiang Jianye Chemical 603948.SS | China | $438M | -36% | -5% | 12% | n/a | -4.3% | +3.5% |
| Trust Chem 001335.SZ | China | $388M | -40% | +5% | 7% | n/a | 24.6% | +5.6% |
| Ho Tung Chemical 1714.TW | Taiwan | $388M | +40% | +48% | 10% | n/a | -20.6% | -1.5% |